Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 12/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31539037 | 0.95 | ERN1 (0.56) | ERN1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL24539357 | 0.95 | ERN1 (0.56) | ERN1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL2353146 | 0.77 | ERN1 (0.56) | ERN1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL544809 | 0.77 | ERN1 (0.78) | ERN1PTGDR2PIM1 | |
| SCHEMBL10322145 | 0.76 | ERN1 (0.44) | ERN1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL26812172 | 0.75 | MEN1 (0.42) | ERN1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL4612055 | 0.74 | MEN1 (0.60) | ERN1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL6765986 | 0.74 | ERN1 (0.39) | ERN1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL28782645 | 0.73 | MEN1 (0.63) | ERN1MEN1MAPTKMT2AKDM4E | |
| SCHEMBL22820404 | 0.72 | ERN1 (0.46) | ERN1MEN1MAPTKMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2484669-B1 | PHENOL DERIVATIVES | FUJI YAKUHIN CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-8367843-B2 | Phenol derivative | FUJI YAKUHIN CO., LTD. (JP) | 2013-02-05 | — | — | US | disclosed |
| CN-102639518-A | Novel Phenol Derivatives | FUJI YAKUHIN CO LTD | 2012-08-15 | — | — | CN | disclosed |
| EP-2484669-A1 | NOVEL PHENOL DERIVATIVE | Fuji Yakuhin Co., Ltd. (JP) | 2012-08-08 | — | — | EP | disclosed |
| US-20120184587-A1 | NOVEL PHENOL DERIVATIVE | FUJI YAKUHIN CO., LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120184587-A1 | NOVEL PHENOL DERIVATIVE | XDH, REN, UTS2R | ERN1 2510/4885MEN1 4797/4885MAPT 3041/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.